Additionally, dasatinib was well tolerated in ACC patients, but only 2.5% (1/20) had OR and 50% (20/40) had SD even with an experimental design that confirmed C-KIT overexpression (78). The gene discussed is KIT; the disease is adrenal cortex carcinoma.